The evolving use of arsenic in pharmacotherapy of malignant disease

Annals of Hematology

Volumn 92, Issue 6, 2013, Pages 719-730

  Kritharis, Athena ^a   Bradley, Thomas P ^a   Budman, Daniel R ^a  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

Arsenic trioxide; Malignancy; Metabolism; Pharmacology; Toxicity

Indexed keywords

A LIN 1; ANTHRACYCLINE; ARSENIC; ARSENIC DERIVATIVE; ARSENIC TETRASULFIDE; ARSENIC TRIOXIDE; ARSENILATE ATOXYL; ARSENITE SODIUM; ARSENOSOBENZENE; ARSINIC ACID DERIVATIVE; ARSPHENAMINE; CACODYLIC ACID; CYTARABINE; DAUNORUBICIN; DIMETHYLARSINOUS ACID; GEMTUZUMAB OZOGAMICIN; HERBACEOUS AGENT; INORGANIC ARSENITE; LIQUID POTASSIUM ARSENITE; METHANEARSONIC ACID; METHYLARSONOUS ACID; REACTIVE OXYGEN METABOLITE; RETINOIC ACID; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; ASTHMA; AUTOIMMUNE DISEASE; BLINDNESS; BREAST CANCER; BREAST METASTASIS; CARCINOGENICITY; CARDIOTOXICITY; CELL FUNCTION; CHOREA; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DENTAL CARIES; DRUG APPROVAL; DRUG DISPOSITION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG TOXICITY; ECZEMA; HUMAN; INTRACELLULAR SIGNALING; LEUKEMIA REMISSION; LOW DRUG DOSE; MALARIA; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEPHRITIS; NONHUMAN; PARESIS; PEMPHIGUS; PERNICIOUS ANEMIA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PSORIASIS; QT PROLONGATION; SOLID TUMOR; SYPHILIS; TACHYCARDIA; TRYPANOSOMIASIS; ULCER;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENIC POISONING; ARSENICALS; BIOTRANSFORMATION; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; GASTROINTESTINAL DISEASES; GENE EXPRESSION REGULATION; HEART DISEASES; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKOCYTOSIS; METABOLIC NETWORKS AND PATHWAYS; METHYLTRANSFERASES; NEOPLASMS; OXIDES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84877772907     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1707-3     Document Type: Article

References (138)

1. Antman KH (2001) Introduction: the history of arsenic trioxide in cancer therapy. Oncologist 6(Suppl 2):1-2
2. Doyle D (2009) Notoriety to respectability: a short history of arsenic prior to its present day use in haematology. Br J Haematol 145(3):309-317
3. Mari F, Bertol E, Fineschi V, Karch SB (2004) Channelling the Emperor: what really killed Napoleon? J R Soc Med 97(8):397-399. doi: 10.1258/jrsm.97.8.397
4. Liu JLY, Wu Q et al (2008) Mineral arsenicals in traditional medicines: orpiment, realgar, and arsenolite. J Pharmacol Exp Ther 326:363-368
5. Miller M (1998) Scientists explore use of arsenic in therapy. J Natl Cancer Inst 90(24):1866-1867
6. Waxman S, Anderson KC (2001) History of the development of arsenic derivatives in cancer therapy. Oncologist 6(Suppl 2):3-10
7. Dilda PJ, Hogg PJ (2007) Arsenical-based cancer drugs. Cancer Treat Rev 33(6):542-564. doi: 10.1016/j.ctrv.2007.05.001
8. Breinl A, Todd JL (1907) Atoxyl in the Treatment of Trypanosomiasis. Br Med J 1(2403):132-134
9. Thorburn AL (1983) Paul Ehrlich: pioneer of chemotherapy and cure by arsenic (1854-1915). Brit J Vener Dis 59(6):404-405
10. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, Li JM, Zeng XY, Yang RR, Yuan MM, Ren MY, Gu FY, Cao Q, Gu BW, Su XY, Chen GQ, Xiong SM, Zhang TD, Waxman S, Wang ZY, Chen Z, Hu J, Shen ZX, Chen SJ (1999) Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94(10):3315-3324
11. Anonymous (2001) Arsenic-based therapy benefits leukemia patients. FDA Consum 35 (1):4
12. Anonymous (2004) Arsenic trioxide: new preparation. (2004) Acute promyelocytic leukaemia: encouraging results but persistent doubts. Prescrire Int 13 (72):135-137
13. Amadori S, Fenaux P, Ludwig H, O'Dwyer M, Sanz M (2005) Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent. Curr Med Res Opin 21(3):403-411. doi: 10.1185/030079904X20349
14. Anderson KC, Boise LH, Louie R, Waxman S (2002) Arsenic trioxide in multiple myeloma: rationale and future directions. Cancer J 8(1):12-25
15. Berenson JR, Boccia R, Siegel D, Bozdech M, Bessudo A, Stadtmauer E, Talisman Pomeroy J, Steis R, Flam M, Lutzky J, Jilani S, Volk J, Wong SF, Moss R, Patel R, Ferretti D, Russell K, Louie R, Yeh HS, Swift RA (2006) Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Br J Haematol 135(2):174-183. doi: 10.1111/j.1365-2141.2006.06280.x
16. Bonati A, Rizzoli V, Lunghi P (2006) Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug. Curr Pharm Biotechnol 7(6):397-405
17. Campbell RA, Sanchez E, Steinberg JA, Baritaki S, Gordon M, Wang C, Shalitin D, Chen H, Pang S, Bonavida B, Said J, Berenson JR (2007) Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid. Br J Haematol 138(4):467-478. doi: 10.1111/j.1365-2141.2007.06675.x
18. Donelli A, Chiodino C, Panissidi T, Roncaglia R, Torelli G (2000) Might arsenic trioxide be useful in the treatment of advanced myelodysplastic syndromes? Haematologica 85(9):1002-1003
19. Hussein MA, Saleh M, Ravandi F, Mason J, Rifkin RM, Ellison R (2004) Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. Br J Haematol 125(4):470-476. doi: 10.1111/j.1365-2141.2004. 04941.x
20. Sekeres MA (2007) New data with arsenic trioxide in leukemias and myelodysplastic syndromes. Clin Lymphoma Myelom 8(Suppl 1):S7-S12
21. Huang SY, Chang CS, Tang JL, Tien HF, Kuo TL, Huang SF, Yao YT, Chou WC, Chung CY, Wang CH, Shen MC, Chen YC (1998) Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia. Br J Haematol 103(4):1092-1095
22. Kwong YL, Todd D (1997) Delicious poison: arsenic trioxide for the treatment of leukemia. Blood 89(9):3487-3488
23. Moore DF, O'Callaghan CA, Berlyne G, Ogg CS, Davies HA, House IM, Henry JA (1994) Acute arsenic poisoning: absence of polyneuropathy after treatment with 2,3-dimercaptopropanesulphonate (DMPS). J Neurol Neurosurg Psychiatry 57(9):1133-1135
24. Ratnaike RN (2003) Acute and chronic arsenic toxicity. Postgrad Med J 79(933):391-396
25. Sankpal UT, Goodison S, Abdelrahim M, Basha R (2011) Targeting sp1 transcription factors in prostate cancer therapy. Med Chem 7(5):518-525
26. Das NK, Sengupta SR (2008) Arsenicosis: diagnosis and treatment. Indian J Dermatol Venereol Leprol 74(6):571-581
27. Sengupta SR, Das NK, Datta PK (2008) Pathogenesis, clinical features and pathology of chronic arsenicosis. Indian J Dermatol Venereol Leprol 74(6):559-570
28. Caldwell KL, Jones RL, Verdon CP, Jarrett JM, Caudill SP, Osterloh JD (2009) Levels of urinary total and speciated arsenic in the US population: National Health and Nutrition Examination Survey 2003-2004. J Expo Sci Environ Epidemiolo 19(1):59-68. doi: 10.1038/jes.2008.32
29. Ablain J, de The H (2011) Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood 117(22):5795-5802. doi: 10.1182/blood-2011- 02-329367
30. Agostinelli E, Seiler N (2006) Non-irradiation-derived reactive oxygen species (ROS) and cancer: therapeutic implications. Amino Acids 31(3):341-355. doi: 10.1007/s00726-005-0271-8
31. Liu Y, Zhang W, Zhang X, Qi Y, Huang D, Zhang Y (2011) Arsenic trioxide inhibits invasion/migration in SGC-7901 cells by activating the reactive oxygen species-dependent cyclooxygenase-2/matrix metalloproteinase-2 pathway. Exp Biol Med 236(5):592-597. doi: 10.1258/ebm.2011.010276
32. Liu Q, Zhang H, Smeester L, Zou F, Kesic M, Jaspers I, Pi J, Fry RC (2010) The NRF2-mediated oxidative stress response pathway is associated with tumor cell resistance to arsenic trioxide across the NCI-60 panel. BMC Med Genomics 3:37. doi: 10.1186/1755-8794-3-37
33. Li JJ, Tang Q, Li Y, Hu BR, Ming ZY, Fu Q, Qian JQ, Xiang JZ (2006) Role of oxidative stress in the apoptosis of hepatocellular carcinoma induced by combination of arsenic trioxide and ascorbic acid. Acta Pharmacol Sin 27(8):1078-1084. doi: 10.1111/j.1745-7254.2006.00345.x
34. Jang M, Kim Y, Won H, Lim S, K.R J, Dashdorj A, Min YH, Kim S-Y, Shokat KM, Ha J, Kim SS (2012) Carbonyl reductase 1 offers a novel therapeutic target to enhance leukemia treatment by arsenic trioxide, vol 72. First published. doi: 10.1158/0008-5472.can-12-1110
35. Binet F, Girard D (2008) Novel human neutrophil agonistic properties of arsenic trioxide: involvement of p38 mitogen-activated protein kinase and/or c-jun NH2-terminal MAPK but not extracellular signal-regulated kinases-1/2. J Leukoc Biol 84(6):1613-1622. doi: 10.1189/jlb.0708421
36. Huang HS, Liu ZM, Cheng YL (2011) Involvement of glycogen synthase kinase-3beta in arsenic trioxide-induced p21 expression. Toxicol Sci 121(1):101-109. doi: 10.1093/toxsci/kfr023
37. Stepnik M, Ferlinska M, Smok-Pieniazek A, Gradecka-Meesters D, Arkusz J, Stanczyk M (2011) Assessment of the involvement of oxidative stress and mitogen-activated protein kinase signaling pathways in the cytotoxic effects of arsenic trioxide and its combination with sulindac or its metabolites: sulindac sulfide and sulindac sulfone on human leukemic cell lines. Med Oncol. doi: 10.1007/s12032-011-9920-1
38. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88(3):1052-1061
39. Catalano A, Dawson MA, Somana K, Opat S, Schwarer A, Campbell LJ, Iland H (2007) The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia. Blood 110(12):4073-4076. doi: 10.1182/blood-2007-06-095554
40. Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou L, Huang Y, Zhang JW, Xiong SM, Chen SJ, Wang ZY, Chen Z, Chen GQ (2000) Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 14(2):262-270
41. Meng R, Zhou J, Sui M, Li Z, Feng G, Yang B (2010) Arsenic trioxide promotes mitochondrial DNA mutation and cell apoptosis in primary APL cells and NB4 cell line. Science China Life Sciences 53(1):87-93. doi: 10.1007/s11427-010-0004-9
42. Lu D, Bai XC, Gui L, Li M, Zheng WS, Han XQ, Luo SQ (2003) Arsenic trioxide-induced apoptosis of human malignant lymphoma cell lines and its mechanisms. Di Yi Jun Yi Da Xue Xue Bao 23(10):997-1001
43. Liu B, Pan S, Dong X, Qiao H, Jiang H, Krissansen GW, Sun X (2006) Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Cancer Sci 97(7):675-681. doi: 10.1111/j.1349-7006.2006.00230.x
44. Liu ZM, Huang HS (2008) Arsenic trioxide phosphorylates c-Fos to transactivate p21(WAF1/CIP1) expression. Toxicol Appl Pharmacol 233(2):297-307. doi: 10.1016/j.taap.2008.08.015
45. Mann KK, Colombo M, Miller WH Jr (2008) Arsenic trioxide decreases AKT protein in a caspase-dependent manner. Mol Cancer Ther 7(6):1680-1687. doi: 10.1158/1535-7163.MCT-07-2164
46. Liu Y, Hock JM, Sullivan C, Fang G, Cox AJ, Davis KT, Davis BH, Li X (2010) Activation of the p38 MAPK/Akt/ERK1/2 signal pathways is required for the protein stabilization of CDC6 and cyclin D1 in low-dose arsenite-induced cell proliferation. J Cell Biochem 111(6):1546-1555. doi: 10.1002/jcb.22886
47. Barginear MF, Leung M, Budman DR (2009) The hedgehog pathway as a therapeutic target for treatment of breast cancer. Breast Cancer Res Treat 116(2):239-246. doi: 10.1007/s10549-009-0423-0
48. Kim J, Lee JJ, Gardner D, Beachy PA (2010) Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. PNAS 107(30):13432-13437. doi: 10.1073/pnas.1006822107
49. Patlolla AK, Tchounwou PB (2005) Cytogenetic evaluation of arsenic trioxide toxicity in Sprague-Dawley rats. Mutat Res 587(1-2):126-133. doi: 10.1016/j.mrgentox.2005.08.007
50. Soriano C, Creus A, Marcos R (2008) Arsenic trioxide mutational spectrum analysis in the mouse lymphoma assay. Mutat Res 646(1-2):1-7. doi: 10.1016/j.mrfmmm.2008.08.014
51. Soriano C, Creus A, Marcos R (2007) Gene-mutation induction by arsenic compounds in the mouse lymphoma assay. Mutat Res 634(1-2):40-50. doi: 10.1016/j.mrgentox.2007.05.014
52. Aballay LR, Diaz MD, Francisca FM, Munoz SE (2011) Cancer incidence and pattern of arsenic concentration in drinking water wells in Cordoba, Argentina. Int J Environ Health Res. doi: 10.1080/09603123.2011.628792
53. Tokar EJ, Qu W, Waalkes MP (2011) Arsenic, stem cells, and the developmental basis of adult cancer. J Toxicol Sci 120(Suppl 1):S192-S203. doi: 10.1093/toxsci/kfq342
54. Le XC, Lu X, Ma M, Cullen WR, Aposhian HV, Zheng B (2000) Speciation of key arsenic metabolic intermediates in human urine. Anal Chem 72(21):5172-5177
55. Carney DA (2008) Arsenic trioxide mechanisms of action - looking beyond acute promyelocytic leukemia. Leuk Lymphoma 49(10):1846-1851
56. Cui X, Kobayashi Y, Akashi M, Okayasu R (2008) Metabolism and the paradoxical effects of arsenic: carcinogenesis and anticancer. Curr Med Chem 15(22):2293-2304
57. Ghosh P, Banerjee M, Giri AK, Ray K (2008) Toxicogenomics of arsenic: classical ideas and recent advances. Mutat Res 659(3):293-301
58. Hernandez A, Marcos R (2008) Genetic variations associated with interindividual sensitivity in the response to arsenic exposure. Pharmacogenomics 9(8):1113-1132
59. Tseng CH (2007) Metabolism of inorganic arsenic and non-cancerous health hazards associated with chronic exposure in humans. J Environ Biol 28(2 Suppl):349-357
60. Tseng CH (2007) Arsenic methylation, urinary arsenic metabolites and human diseases: current perspective. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 25(1):1-22
61. Vahter M, Akesson A, Liden C, Ceccatelli S, Berglund M (2007) Gender differences in the disposition and toxicity of metals. Environ Res 104(1):85-95
62. Ghosh P, Banerjee M, Giri AK, Ray K (2008) Toxicogenomics of arsenic: classical ideas and recent advances. Mutat Res 659(3):293-301
63. Thomas DJ, Li J, Waters SB, Xing W, Adair BM, Drobna Z, Devesa V, Styblo M (2007) Arsenic (+3 oxidation state) methyltransferase and the methylation of arsenicals. Exp Biol Med 232(1):3-13
64. Charoensuk V, Gati WP, Weinfeld M, Le XC (2009) Differential cytotoxic effects of arsenic compounds in human acute promyelocytic leukemia cells. Toxicol Appl Pharmacol 239(1):64-70. doi: 10.1016/j.taap.2009.05.016
65. Drobna Z, Walton FS, Harmon AW, Thomas DJ, Styblo M (2010) Interspecies differences in metabolism of arsenic by cultured primary hepatocytes. Toxicol Appl Pharmacol 245(1):47-56. doi: 10.1016/j.taap.2010.01.015
66. Styblo M, Del Razo LM, LeCluyse EL, Hamilton GA, Wang C, Cullen WR, Thomas DJ (1999) Metabolism of arsenic in primary cultures of human and rat hepatocytes. Chem Res Toxicol 12(7):560-565. doi: 10.1021/tx990050l
67. Hirano S, Kobayashi Y, Cui X, Kanno S, Hayakawa T, Shraim A (2004) The accumulation and toxicity of methylated arsenicals in endothelial cells: important roles of thiol compounds. Toxicol Appl Pharmacol 198(3):458-467
68. Waters SB, Devesa V, Fricke MW, Creed JT, Styblo M, Thomas DJ (2004) Glutathione modulates recombinant rat arsenic (+3 oxidation state) methyltransferase-catalyzed formation of trimethylarsine oxide and trimethylarsine. Chem Res Toxicol 17(12):1621-1629. doi: 10.1021/tx0497853
69. Hirano S, Kobayashi Y, Cui X, Kanno S, Hayakawa T, Shraim A (2004) The accumulation and toxicity of methylated arsenicals in endothelial cells: important roles of thiol compounds. Toxicol Appl Pharmacol 198(3):458-467
70. Thomas DJ, Styblo M, Lin S (2001) The cellular metabolism and systemic toxicity of arsenic. Toxicol Appl Pharmacol 176(2):127-144
71. Valenzuela OL, Borja-Aburto VH, Garcia-Vargas GG, Cruz-Gonzalez MB, Garcia-Montalvo EA, Calderon-Aranda ES, Del Razo LM (2005) Urinary trivalent methylated arsenic species in a population chronically exposed to inorganic arsenic. Environ Health Perspect 113(3):250-254
72. Thomas DJ, Styblo M, Lin S (2001) The cellular metabolism and systemic toxicity of arsenic. Toxicol Appl Pharmacol 176(2):127-144
73. Cohen SM, Arnold LL, Eldan M, Lewis AS, Beck BD (2006) Methylated arsenicals: the implications of metabolism and carcinogenicity studies in rodents to human risk assessment. Crit Rev Toxicol 36(2):99-133
74. Raml R, Rumpler A, Goessler W, Vahter M, Li L, Ochi T, Francesconi KA (2007) Thio-dimethylarsinate is a common metabolite in urine samples from arsenic-exposed women in Bangladesh. Toxicol Appl Pharmacol 222(3):374-380
75. Wang Z, Zhou J, Lu X, Gong Z, Le XC (2004) Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Chem Res Toxicol 17(1):95-103
76. Lin CJ, Wu MH, Hsueh YM, Sun SS, Cheng AL (2005) Tissue distribution of arsenic species in rabbits after single and multiple parenteral administration of arsenic trioxide: tissue accumulation and the reversibility after washout are tissue-selective. Cancer Chemother Pharmacol 55(2):170-178
77. Hernandez-Zavala A, Matousek T, Drobna Z, Paul DS, Walton F, Adair BM, Jiri D, Thomas DJ, Styblo M (2008) Speciation analysis of arsenic in biological matrices by automated hydride generation-cryotrapping-atomic absorption spectrometry with multiple microflame quartz tube atomizer (multiatomizer). J Anal At Spectrom 23:342-351
78. Slejkovec Z, Falnoga I, Goessler W, van Elteren JT, Raml R, Podgornik H, Cernelc P (2008) Analytical artefacts in the speciation of arsenic in clinical samples. Anal Chim Acta 607(1):83-91
79. Schlawicke Engstrom K, Nermell B, Concha G, Stromberg U, Vahter M, Broberg K (2009) Arsenic metabolism is influenced by polymorphisms in genes involved in one-carbon metabolism and reduction reactions. Mutat Res 667:4-14
80. Hernandez A, Xamena N, Surralles J, Sekaran C, Tokunaga H, Quinteros D, Creus A, Marcos R (2008) Role of the Met(287)Thr polymorphism in the AS3MT gene on the metabolic arsenic profile. Mutat Res 637(1-2):80-92
81. Fujihara J, Fujii Y, Agusa T, Kunito T, Yasuda T, Moritani T, Takeshita H (2009) Ethnic differences in five intronic polymorphisms associated with arsenic metabolism within human arsenic (+3 oxidation state) methyltransferase (AS3MT) gene. Toxicol Appl Pharmacol 234(1):41-46
82. De Chaudhuri S, Ghosh P, Sarma N, Majumdar P, Sau TJ, Basu S, Roychoudhury S, Ray K, Giri AK (2008) Genetic variants associated with arsenic susceptibility: study of purine nucleoside phosphorylase, arsenic (+3) methyltransferase, and glutathione S-transferase omega genes. Environ Health Perspect 116(4):501-505
83. Calderon RL, Hudgens E, Le XC, Schreinemachers D, Thomas DJ (1999) Excretion of arsenic in urine as a function of exposure to arsenic in drinking water. Environ Health Perspect 107(8):663-667
84. Ghaffari SH, Rostami S, Bashash D, Alimoghaddam K, Ghavamzadeh A (2006) Real-time PCR analysis of PML-RAR alpha in newly diagnosed acute promyelocytic leukaemia patients treated with arsenic trioxide as a front-line therapy. Ann Oncol 17(10):1553-1559. doi: 10.1093/annonc/mdl150
85. Lo-Coco F, Ammatuna E (2006) The biology of acute promyelocytic leukemia and its impact on diagnosis and treatment. Hematology Am Soc Hematol Educ Program 156-161:514. doi: 10.1182/asheducation-2006.1.156
86. Bachleitner-Hofmann T, Kees M, Gisslinger H (2002) Arsenic trioxide: acute promyelocytic leukemia and beyond. Leuk Lymphoma 43(8):1535-1540. doi: 10.1080/1042819021000002857
87. Shen Y, Shen ZX, Yan H, Chen J, Zeng XY, Li JM, Li XS, Wu W, Xiong SM, Zhao WL, Tang W, Wu F, Liu YF, Niu C, Wang ZY, Chen SJ, Chen Z (2001) Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage. Leukemia 15(5):735-741
88. Ghavamzadeh A, Alimoghaddam K, Rostami S, Ghaffari SH, Jahani M, Iravani M, Mousavi SA, Bahar B, Jalili M (2011) Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol 29(20):2753-2757. doi: 10.1200/JCO.2010.32.2107
89. Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, Couban S, Appelbaum FR, Tallman MS, Larson RA (2010) Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 116(19):3751-3757. doi: 10.1182/blood-2010-02-269621
90. Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H (2009) Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 27(4):504-510. doi: 10.1200/JCO.2008.18.6130
91. Gore SD, Gojo I, Sekeres MA, Morris L, Devetten M, Jamieson K, Redner RL, Arceci R, Owoeye I, Dauses T, Schachter-Tokarz E, Gallagher RE (2010) Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol 28(6):1047-1053. doi: 10.1200/JCO.2009.25.5158
92. Lo-Coco F AG, Orlando SM, Ferrara F, Vignetti M, Paola Fazi, Eros Di Bona, Giorgina S (2012) ATRA and arsenic trioxide (ATO) versus atra and idarubicin (AIDA) for newly diagnosed, non high-risk acute promyelocytic leukemia (APL): results of the Phase III, Prospective, Randomized, Intergroup APL0406 Study by the Italian-German Cooperative Groups Gimema-SAL-AMLSG. In: 54th ASH Annual Meeting and Exposition, Atlanta, GA
93. Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM, Li JM, Tang W, Zhao WL, Wu W, Sun HP, Chen QS, Chen B, Zhou GB, Zelent A, Waxman S, Wang ZY, Chen SJ, Chen Z (2009) Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci 106(9):3342-3347. doi: 10.1073/pnas.0813280106
94. Mathews BG V, Lakshmi KM et al (2006) Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 107:2627-2632
95. Lu D-P, Qiu J-Y, Jiang B, Wang Q, Liu K-Y, Liu Y-R, Chen S-S (2002) Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report, vol 99. doi: 10.1182/blood.V99.9.3136
96. Au WY, Kumana CR, Kou M, Mak R, Chan GC, Lam CW, Kwong YL (2003) Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood 102(1):407-408. doi: 10.1182/blood-2003-01-0298
97. Au WY, Kumana CR, Lee HK, Lin SY, Liu H, Yeung DY, Lau JS, Kwong YL (2011) Oral arsenic trioxide based maintenance regimens for first complete remission of acute promyelocytic leukemia: a ten-year follow-up study. Blood. doi: 10.1182/blood-2011-05-354530
98. Baj G, Arnulfo A, Deaglio S, Mallone R, Vigone A, De Cesaris MG, Surico N, Malavasi F, Ferrero E (2002) Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects. Breast Cancer Res Treat 73(1):61-73
99. Diaz Z, Colombo M, Mann KK, Su H, Smith KN, Bohle DS, Schipper HM, Miller WH Jr (2005) Trolox selectively enhances arsenic-mediated oxidative stress and apoptosis in APL and other malignant cell lines. Blood 105(3):1237-1245. doi: 10.1182/blood-2004-05-1772
100. Diaz Z, Laurenzana A, Mann KK, Bismar TA, Schipper HM, Miller WH Jr (2007) Trolox enhances the anti-lymphoma effects of arsenic trioxide, while protecting against liver toxicity. Leukemia 21(10):2117-2127. doi: 10.1038/sj.leu.2404891
101. Martinez-Outschoorn UE, Goldberg A, Lin Z, Ko YH, Flomenberg N, Wang C, Pavlides S, Pestell RG, Howell A, Sotgia F, Lisanti MP (2011) Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biol Ther 12(10)
102. Zhang W, Wang L, Fan Q, Wu X, Wang F, Wang R, Ma Z, Yang J, Lu SH (2011) Arsenic trioxide re-sensitizes ER alpha-negative breast cancer cells to endocrine therapy by restoring ER alpha expression in vitro and in vivo. Oncol Rep 26(3):621-628. doi: 10.3892/or.2011.1352
103. Alsina M (2003) Multiple myeloma: increasing our treatment options. Cancer Control 10(5):357-358
104. Berenson JR, Yellin O (2008) New drugs in multiple myeloma. Curr Opin Support Palliat Care 2(3):204-210. doi: 10.1097/SPC.0b013e3283090475
105. Chanan-Khan AA, Borrello I, Lee KP, Reece DE (2010) Development of target-specific treatments in multiple myeloma. Br J Haematol 151(1):3-15. doi: 10.1111/j.1365-2141.2010.08262.x
106. Gan F, Cao B, Wu D, Chen Z, Hou T, Mao X (2011) Exploring old drugs for the treatment of hematological malignancies. Curr Med Chem 18(10):1509-1514
107. Hayden PJ, Mitsiades CS, Anderson KC, Richardson PG (2007) Novel therapies in myeloma. Curr Opin Hematol 14(6):609-615. doi: 10.1097/MOH. 0b013e3282f0e948
108. Sanaat Z, Rezazadeh M, Vaez Gharamaleki J, Eivazi Ziae J, Esfahani A (2011) Arsenic trioxide in patients with refractory multiple myeloma: a prospective, phase II, single-arm study. Acta Med Iran 49(8):504-508
109. Wen J, Feng Y, Huang W, Chen H, Liao B, Rice L, Preti HA, Kamble RT, Zu Y, Ballon DJ, Chang CC (2010) Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition. Leuk Res 34(1):85-92. doi: 10.1016/j.leukres.2009.05.024
110. Munshi NCDR, Zangari M (1999) Marked anti-tumor effect of arsenic trioxide (As2O3) in high risk refractory multiple myeloma. Blood 94:123a
111. Schiller GJ, Slack J, Hainsworth JD, Mason J, Saleh M, Rizzieri D, Douer D, List AF (2006) Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol 24(16):2456-2464. doi: 10.1200/JCO.2005.03.7903
112. Merkel O, Heyder C, Asslaber D, Hamacher F, Tinhofer I, Holler C, Stocher M, Prokesch A, Papak C, Scheideler M, Trajanoski Z, Greil R (2008) Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13. J Mol Med 86(5):541-552. doi: 10.1007/s00109-008-0314-6
113. Wetzler M, Andrews C, Ford LA, Tighe S, Barcos M, Sait SN, Block AW, Nowak NJ, Baer MR, Wang ES, Baumann H (2011) Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia. Cancer 117(21):4831-4868. doi: 10.1002/cncr.26097
114. Pettersson HM, Pietras A, Munksgaard Persson M, Karlsson J, Johansson L, Shoshan MC, Pahlman S (2009) Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells. Mol Cancer Ther 8(1):160-170. doi: 10.1158/1535-7163.MCT- 08-0595
115. Li N, Song Y, Zhou J, Fang B (2012) Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia. J Hem and Oncol 5(61). doi: 1069344-990823
116. Lin Q, Song Y, Fang B (2012) Arsenic trioxide for refractory aplastc anemia. Ann Hematol. doi: 10.1007/s00277-012-1605-0
117. Sigmon C, Patch S (2010) A pilot survey of in-service home arsenic tracked in from chromated copper arsenate-treated decks. J Environ Health 72(6):18-22
118. Sengupta SR, Das NK, Datta PK (2008) Pathogenesis, clinical features and pathology of chronic arsenicosis. Indian J Dermatol Venereol Leprol 74(6):559-570
119. Lin CC, Pu YS, Hsu CH, Keng HY, Cheng AL, Yang CH (2008) Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma. Urol Oncol 26(6):659-661
120. Tseng CH, Huang YK, Huang YL, Chung CJ, Yang MH, Chen CJ, Hsueh YM (2005) Arsenic exposure, urinary arsenic speciation, and peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan. Toxicol Appl Pharmacol 206(3):299-308
121. Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, Shinjo K, Fujita Y, Matsui H, Takeshita A, Sugiyama S, Satoh H, Terada H, Ohno R (2000) Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 133(11):881-885
122. Unnikrishnan D, Dutcher JP, Varshneya N, Lucariello R, Api M, Garl S, Wiernik PH, Chiaramida S (2001) Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 97(5):1514-1516
123. Raffoux ERP, Poupon J, Daniel MT, Cassinat B, Delarue R, Taksin AL (2003) Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 21(12):2326-2334
124. Tallman MS, Altman JK (2009) How I treat acute promyelocytic leukemia. Blood 114(25):5126-5135. doi: 10.1182/blood-2009-07-216457
125. Navas-Acien ASE, Pastor-Barriuso R et al (2008) Arsenic exposure and prevalence of type 2 diabetes in US adults. JAMA 200:814-822
126. Coronado-Gonzalez JA, Del Razo LM, Garcia-Vargas G, Sanmiguel-Salazar F, Escobedo-de la Pena J (2007) Inorganic arsenic exposure and type 2 diabetes mellitus in Mexico. Environ Res 104(3):383-389
127. Yen CC, Lu FJ, Huang CF, Chen WK, Liu SH, Lin-Shiau SY (2007) The diabetogenic effects of the combination of humic acid and arsenic: in vitro and in vivo studies. Toxicol Lett 172(3):91-105
128. Navas-Acien A, Silbergeld EK, Streeter RA, Clark JM, Burke TA, Guallar E (2006) Arsenic exposure and type 2 diabetes: a systematic review of the experimental and epidemiological evidence. Environ Health Perspect 114(5):641-648
129. Diaz-Villasenor A, Burns AL, Hiriart M, Cebrian ME, Ostrosky-Wegman P (2007) Arsenic-induced alteration in the expression of genes related to type 2 diabetes mellitus. Toxicol Appl Pharmacol 225(2):123-133
130. Kritharis A BT, Budman DR (2011) Association of diabetes mellitus with arsenic trioxide (ATO) evaluated in the treatment of acute promyelocytic leukemia (APL). Proc ASCO Abstract no. e19724
131. Tapio S, Grosche B (2006) Arsenic in the aetiology of cancer. Mutat Res 612(3):215-246
132. Agency USEP (1999) Integrated Risk Information System (IRIS) on Arsenic. National Center for Environmental Assessment, Office of Research and Development
133. Chen CJ, Chuang YC, Lin TM, Wu HY (1985) Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res 45(11 Pt 2):5895-5899
134. Marshall G, Ferreccio C, Yuan Y, Bates MN, Steinmaus C, Selvin S, Liaw J,
135. Mass MJ, Tennant A, Roop BC, Cullen WR, Styblo M, Thomas DJ, Kligerman AD (2001) Methylated trivalent arsenic species are genotoxic. Chem Res Toxicol 14(4):355-361
136. Kitchin KT (2001) Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol Appl Pharmacol 172(3):249-261. doi: 10.1006/taap.2001.9157
137. Cuzick J, Evans S, Gillman M, Price Evans DA (1982) Medicinal arsenic and internal malignancies. Br J Cancer 45(6):904-911
138. Mathews V, George B, Chendamarai E, Lakshmi KM, Desire S, Balasubramanian P, Viswabandya A, Thirugnanam R, Abraham A, Shaji RV, Srivastava A, Chandy M (2010) Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol 28(24):3866-3871. doi: 10.1200/JCO.2010.28.5031